ADT, antidepressant treatment; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; SE, standard error.

References: 1. IQVIA NPA Data. May 2025. 2. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224-1231. 3. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major
depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240. 4. Otsuka Pharmaceutical Co., Ltd; H. Lundbeck A/S. U.S. FDA approves Otsuka and Lundbeck’s REXULTI® (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia. Otsuka America Pharmaceutical, Inc. Published July 10, 2015. Accessed July 17, 2025. https://www.otsuka-us.com/news/us-fda-approves-otsuka-and-lundbecks-rexultir-brexpiprazole-adjunctive-treatment-adults-major